Axiom Investors LLC DE Purchases 148,116 Shares of Insmed, Inc. $INSM

Axiom Investors LLC DE grew its position in Insmed, Inc. (NASDAQ:INSM) by 137.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 255,849 shares of the biopharmaceutical company’s stock after buying an additional 148,116 shares during the period. Axiom Investors LLC DE’s holdings in Insmed were worth $44,528,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. CIBC Private Wealth Group LLC lifted its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new stake in shares of Insmed during the 4th quarter worth about $27,000. SBI Securities Co. Ltd. lifted its stake in shares of Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 166 shares during the last quarter. GraniteShares Advisors LLC acquired a new stake in shares of Insmed during the 4th quarter worth about $30,000. Finally, RiverPark Advisors LLC acquired a new stake in shares of Insmed during the 3rd quarter worth about $38,000.

Insmed Price Performance

NASDAQ:INSM opened at $99.04 on Wednesday. Insmed, Inc. has a 52 week low of $86.00 and a 52 week high of $212.75. The firm has a market cap of $21.47 billion, a price-to-earnings ratio of -17.22 and a beta of 0.79. The firm’s 50-day simple moving average is $128.45 and its 200 day simple moving average is $153.16. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The business had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same period last year, the firm earned ($1.42) earnings per share. Insmed’s revenue for the quarter was up 229.7% compared to the same quarter last year. As a group, sell-side analysts predict that Insmed, Inc. will post -2.56 earnings per share for the current year.

Insider Activity

In other Insmed news, insider Michael Alexander Smith sold 19,638 shares of the firm’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24. Following the transaction, the insider directly owned 51,871 shares of the company’s stock, valued at $7,831,483.58. This trade represents a 27.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 160,482 shares of company stock valued at $24,438,193 in the last 90 days. 2.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on INSM. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Roth Mkm restated a “buy” rating on shares of Insmed in a research note on Monday. Truist Financial cut their target price on shares of Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. JPMorgan Chase & Co. lowered their price target on shares of Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Wells Fargo & Company lowered their price target on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed has an average rating of “Moderate Buy” and an average price target of $212.50.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.